Phase II study of ramucirumab plus docetaxel plus pegfilgrastim with stage IV non-small cell lung cancer patients

Trial Profile

Phase II study of ramucirumab plus docetaxel plus pegfilgrastim with stage IV non-small cell lung cancer patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Docetaxel (Primary) ; Pegfilgrastim (Primary) ; Ramucirumab (Primary)
  • Indications Neutropenia; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 14 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top